Summary of Key Points
Shenzhen Yimu Feng Biology is a six-year-old, unprofitable biotech company with no products on the market, currently making a second attempt to go public on the Hong Kong Stock Exchange (IPO). Its only product capable of supporting an IPO is IMC002, a CLDN18.2-targeted CAR-T therapy for solid tumors such as gastric cancer. However, a recent death of a 49-year-old gastric cancer patient during the clinical trial of IMC002 has raised concerns about insufficient informed consent and potential drug-related issues. Coupled with the company's nearly 300 million yuan in losses over the past two and a half years, with 80% of research and development funds invested in IMC002, and the multiple challenges faced by the solid tumor CAR-T industry in terms of safety and commercialization, Yimu Feng's IPO path has become highly risky.
1. Death Incident: Sudden Brain Herniation on the Day of Drug Administration
In early 2026, a 49-year-old gastric cancer patient enrolled in the IMC002 clinical trial. Several hours after receiving the drug, the patient suffered from bilateral subdural hematomas (severe brain bleeding) and subsequently developed a brain herniation, leading to death despite craniotomy. The family raised two main concerns:
1. Insufficient Informed Consent: The trial information sheet only vaguely mentioned the risk of bleeding disorders without specifying the life-threatening risk of severe brain bleeding, which they believed violated their right to be informed and to make choices.
2. Potential Drug Association: The patient was in relatively good condition after chemotherapy when the incident occurred, leading the family to suspect a connection with IMC002.
Yimu Feng responded by stating it would cooperate with the investigation but insisted that the death was likely a side effect of chemotherapy, offering only humanitarian compensation rather than legal damages. Although the official cause of death has not yet been determined, the incident occurred during a critical period for the IPO, significantly impacting the company's prospects.
2. The Core Product IMC002: Promising Data but Limited Sample Size
IMC002 is Yimu Feng's lifeline, considered the second-fastest-developing CLDN18.2 CAR-T therapy globally (after Kite Pharma's commercially available Kailimei).
- Positive Early Results: In Phase I/IIa trials, the tumor response rate (ORR) in the recommended dose group reached 69.2% (significantly higher than the 2.8% for current standard treatments), with some patients experiencing complete tumor remission that lasted for 70 weeks.
- Limited Sample Size: Only 29 participants were enrolled, all of whom were carefully selected as “healthy” patients (excluding those with brain metastases or high bleeding risks), so the data may not reflect the real-world situation.
- Phase III as the Decisive Test: A Phase III trial with 150 diverse patients is necessary to meet regulatory requirements. Any safety issues in Phase III could dash IMC002's chances of approval.
3. Company Survival Depends on IMC002: Financial Strains
Yimu Feng's survival is entirely tied to IMC002:
- High-Risk R&D: From 2024 to the first half of 2026, the company invested 214 million yuan in R&D, of which 76.8% went towards IMC002 (80% of the total R&D expenditure).
- Severe Losses: With nearly 300 million yuan in losses over two and a half years, as of June 2026, the company had only about 400 million yuan in cash. At the current rate of expenditure, its funds would last for 21 months.
- IPO as a Lifeline: The funds raised will primarily be used for Phase III trials and commercialization of IMC002. A failed IPO could lead to a financial crisis.
4. Industry Challenges: Frequent Safety Issues with CAR-T Therapies and Barriers to Commercialization of Solid Tumor Therapies
Even if IMC002 is approved, Yimu Feng faces industry-wide challenges:
1. Common Safety Risks: Multiple companies have experienced deaths in CAR-T trials (e.g., Juno's JCAR015 was discontinued due to brain edema), and the safety issues with solid tumor CAR-T therapies are even more complex.
2. High Cost and Limited Market Access: CAR-T therapies are expensive (e.g., Kailimei costs 990,000 yuan per dose), with slow coverage by health insurance and difficulty in hospital adoption, resulting in limited sales.
3. High Costs: Autologous CAR-T therapies are costly and time-consuming (patient cells are collected, modified, and reinfused), further squeezing profit margins. Additionally, since IMC002 uses licensed technology, the company will have to pay royalties, further reducing profits.
4. Market Skepticism: After Kite Pharma's Kailimei was approved, its stock price dropped by 26%, indicating investors' cautious attitude towards the commercialization of solid tumor CAR-T therapies.
5. The IPO on Hold: The Death Incident as a Critical Factor
Yimu Feng's second attempt to list on the Hong Kong Stock Exchange follows the “18A” regulation, which allows unprofitable biotech companies to go public, with the condition that their core products must be in ongoing development beyond the conceptual stage.
- Disclosure Required: If the death is confirmed to be a major safety issue, Yimu Feng must provide detailed explanations in its prospectus, which could affect investor confidence.
- Potential Hurdles in Phase III: If the death is linked to the drug, Phase III trials could be halted or delayed, potentially preventing the company from meeting the 18A requirements.
- High Uncertainty: Even if the IPO is successful, IMC002's commercialization will face significant challenges, and its stock price may perform similarly to Kite Pharma's.
In summary, Yimu Feng's “bridge to success” is showing signs of weakness, and the road ahead is fraught with difficulties. A company relying on a single product to survive is facing safety issues and various industry hurdles, making its IPO outcome and future prospects very uncertain.